JOSE ANTONIO
IRIBARREN LOYARTE
PROFESORADO AGREGADO
![Foto de JOSE ANTONIO](/img/nophoto.png)
![Foto de Hospital Universitario de la Princesa](/img/noimage_org.png)
Hospital Universitario de la Princesa
Madrid, EspañaPublications in collaboration with researchers from Hospital Universitario de la Princesa (50)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Viruses, Vol. 15, Núm. 2
-
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Frontiers in Cellular and Infection Microbiology, Vol. 13
-
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Viruses, Vol. 15, Núm. 4
-
Human IgMhiCD300a+ B Cells Are Circulating Marginal Zone Memory B Cells That Respond to Pneumococcal Polysaccharides and Their Frequency Is Decreased in People Living with HIV
International Journal of Molecular Sciences, Vol. 24, Núm. 18
-
Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021
Journal of Medical Virology, Vol. 95, Núm. 12
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens
Frontiers in Immunology, Vol. 13
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684
-
Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study
BMC Infectious Diseases, Vol. 21, Núm. 1
2020
-
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
-
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
Scientific Reports, Vol. 9, Núm. 1
-
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700
-
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170